Clinical Trial Update: Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients [Phase 2]

View source ↗

Summary

Phase II trial evaluating vorinostat (SAHA) in combination with bevacizumab for recurrent malignant glioma, including glioblastoma. The study is completed and r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Malignant Glioma

Drugs mentioned

• Avastin (bevacizumab)
• Zolinza (vorinostat)

Snippet

Sponsor: Duke University | Conditions: Recurrent Glioblastoma Multiforme, Malignant Glioma | Phase 2 | Status: COMPLETED | Results posted: 2015-10-29